Fig. 2
From: Differential response to donepezil in MRI subtypes of mild cognitive impairment
Design and protocol of the Hippocampus Study Clinical Trial (www.clinialTrial.gov; identifier: NCT00403520). The Hippocampus Study Clinical Trial extended for up to 18 months, consisting of a 4-week selection period (visit 0), a 12-month randomized double-blind treatment window (visits 1–4), and an open label extension period of 6 more months (visits 4–5). At the treatment window, individuals were randomly assigned to either the active treatment group or the placebo control group. The treatment group received 1 capsule of 5-mg donepezil daily from week 0 to 6, then 2 capsules of 5-mg donepezil (i.e. 10 mg) until month 12; the placebo group received 1 placebo capsule daily until week 6, and then two placebo capsules until month 12